Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moderna, Inc. (MRNA : NSDQ)
 
 • Company Description   
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.

Number of Employees: 2,700

 
 • Price / Volume Information   
Yesterday's Closing Price: $136.25 Daily Weekly Monthly
20 Day Moving Average: 6,845,117 shares
Shares Outstanding: 397.76 (millions)
Market Capitalization: $54,194.73 (millions)
Beta: 1.70
52 Week High: $497.49
52 Week Low: $119.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.91% 6.30%
12 Week -9.97% 1.19%
Year To Date -46.35% -34.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 TECHNOLOGY SQUARE
-
CAMBRIDGE,MA 02139
USA
ph: 617-714-6500
fax: -
ir@modernatx.com http://www.modernatx.com
 
 • General Corporate Information   
Officers
Stephane Bancel - Chief Executive Officer
Noubar B. Afeyan - Chairman
David Meline - Chief Financial Officer
Stephen Berenson - Director
Sandra Horning - Director

Peer Information
Moderna, Inc. (CORR.)
Moderna, Inc. (RSPI)
Moderna, Inc. (CGXP)
Moderna, Inc. (BGEN)
Moderna, Inc. (GTBP)
Moderna, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60770K107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 397.76
Most Recent Split Date: (:1)
Beta: 1.70
Market Capitalization: $54,194.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $4.72 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $27.22 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 6.51% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 5.01
Trailing 12 Months: 4.00
PEG Ratio: 0.77
Price Ratios
Price/Book: 3.17
Price/Cash Flow: 4.42
Price / Sales: 2.40
EPS Growth
vs. Year Ago Period: 202.11%
vs. Previous Quarter: -24.00%
Sales Growth
vs. Year Ago Period: 213.16%
vs. Previous Quarter: -15.88%
ROE
03/31/22 - 121.86
12/31/21 - 140.21
09/30/21 - 121.61
ROA
03/31/22 - 65.53
12/31/21 - 65.57
09/30/21 - 49.46
Current Ratio
03/31/22 - 1.77
12/31/21 - 1.76
09/30/21 - 1.35
Quick Ratio
03/31/22 - 1.56
12/31/21 - 1.60
09/30/21 - 1.25
Operating Margin
03/31/22 - 64.77
12/31/21 - 66.06
09/30/21 - 59.69
Net Margin
03/31/22 - 64.77
12/31/21 - 66.06
09/30/21 - 59.69
Pre-Tax Margin
03/31/22 - 71.92
12/31/21 - 71.92
09/30/21 - 64.27
Book Value
03/31/22 - 42.93
12/31/21 - 34.89
09/30/21 - 24.97
Inventory Turnover
03/31/22 - 2.76
12/31/21 - 2.95
09/30/21 - 3.11
Debt-to-Equity
03/31/22 - 0.04
12/31/21 - 0.04
09/30/21 - 0.02
Debt-to-Capital
03/31/22 - 3.65
12/31/21 - 4.06
09/30/21 - 2.30
 

Powered by Zacks Investment Research ©